- Report
- May 2024
- 135 Pages
Global
From €3541EUR$3,999USD£3,060GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4384EUR$4,950USD£3,788GBP
- Report
- April 2025
- 192 Pages
Global
From €4423EUR$4,995USD£3,822GBP
- Report
- May 2023
- 260 Pages
Global
From €2347EUR$2,650USD£2,028GBP
- Report
- November 2023
- 109 Pages
Global
From €3500EUR$4,234USD£3,130GBP
- Report
- November 2025
- 132 Pages
Global
From €841EUR$950USD£727GBP
The Urinary Incontinence Drug market is a subset of the Urological Disorders Drugs market, which includes drugs used to treat a variety of conditions related to the urinary system. Urinary Incontinence Drugs are used to treat the involuntary leakage of urine, which can be caused by a variety of conditions, including overactive bladder, stress incontinence, and urge incontinence. These drugs can be administered orally, topically, or through injections. Commonly used drugs include anticholinergics, beta-3 agonists, and alpha-blockers.
Some of the companies in the Urinary Incontinence Drug market include Allergan, Astellas Pharma, Pfizer, Merck, and Sanofi. Show Less Read more